SCHEDULE 13D
Item 1. | Security and Issuer |
This Amendment No. 5 (“Amendment No. 5”) supplements and amends the Schedule 13D relating to shares of common stock, par value $0.0001 per share (the “Common Stock”), of RAPT Therapeutics, Inc., a Delaware corporation (the “Issuer”) that was filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2019 as it was amended by Amendment No. 1 thereto filed with the SEC on February 14, 2020, Amendment No. 2 thereto filed with the SEC on August 26, 2020, Amendment No. 3 thereto filed with the SEC on October 1, 2020, and Amendment No. 4 thereto filed with the SEC on August 30, 2021 (collectively, the “Amended Statement”). Only those items that are reported are hereby amended; all other items reported in the Amended Statement remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Amended Statement. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.
Item 5. | Interest in Securities of the Issuer |
Solely on behalf of, and only to the extent that it relates to the Reporting Persons, Item 5 of the Original 13D is hereby amended as follows:
(a) and (b) See Items 7-11 of the cover pages of this Amendment No. 5.
(c) On September 10, 2021, TCG II LP effected a pro rata distribution without additional consideration of 1,166,666 shares of Common Stock to (i) TCG II GP LP, its general partner and (ii) its limited partners. TCG II GP LP then effected a pro rata distribution without additional consideration of the shares that it received in connection with such distribution to its members (the “Distribution”).
On September 10, 2021, TCG LLC received 72 shares in the Distribution.
On September 10, 2021, Peter Svennilson received 84,307 shares in the Distribution.
On September 10, 2021, David V. Goeddel received 84,307 shares in the Distribution.
On September 10, 2021, Timothy Kutzkey received 48,652 shares in the Distribution.
On September 10, 2021, Peter Svennilson sold 7,320 Common Shares at a weighted average price per share of $35.1875 for aggregate proceeds of approximately $257,572.50.
On September 10, 2021, David V. Goeddel sold 7,187 Common Shares at a weighted average price per share of $35.1941 for aggregate proceeds of approximately $252,939.99.
On September 10, 2021, Timothy Kutzkey sold 7,231 Common Shares at a weighted average price per share of $35.1949 for aggregate proceeds of approximately $254,494.32.
On September 13, 2021, Peter Svennilson sold 4,726 Common Shares at a weighted average price per share of $35.2713 for aggregate proceeds of approximately $166,692.16.
On September 13, 2021, David V. Goeddel sold 4,803 Common Shares at a weighted average price per share of $35.2506 for aggregate proceeds of approximately $169,308.63.
On September 13, 2021, Timothy Kutzkey sold 4,788 Common Shares at a weighted average price per share of $35.2845 for aggregate proceeds of approximately $168,942.19.
On September 14, 2021, Peter Svennilson sold 1,400 Common Shares at a weighted average price per share of $35.7071 for aggregate proceeds of approximately $49,989.94.
On September 14, 2021, Peter Svennilson sold 29,634 Common Shares at a weighted average price per share of $36.7869 for aggregate proceeds of approximately $1,090,142.99.